• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

An­a­lysts write off Di­men­sion’s lead pro­gram af­ter see­ing weak da­ta on he­mo­phil­ia B, shares plunge

9 years ago
Pharma

Eli Lil­ly shut­ters the last PhI­II so­la study, cer­tain of fail­ure

9 years ago
R&D

Pfiz­er prunes three drugs from its pipeline; Astel­las in-li­cens­es ear drug

9 years ago
News Briefing

Trump scolds phar­ma ex­ecs, de­mand­ing low­er prices, more US man­u­fac­tur­ing while promis­ing to slash FDA regs

9 years ago
Pharma

Tenax en­dures (an­oth­er) clin­i­cal cat­a­stro­phe as its PhI­II flops, shares blitzed

9 years ago
R&D

On a deal spree, Take­da grabs Japan­ese cabo rights in $145M pact with Ex­elix­is

9 years ago
Pharma

An­oth­er top Genen­tech ex­ec gets poached, this time tak­ing the helm at CAR-T play­er Bel­licum

9 years ago
People

Big Phar­ma CEOs get a face-to-face with Trump and a shot at a ne­go­ti­at­ed cease fire

9 years ago
Bioregnum
Opinion

Af­ter a PhII cat­a­stro­phe wiped out a bil­lion dol­lars in mar­ket cap, Seres is look­ing for a do-over

9 years ago
R&D

uniQure wins a BTD for he­mo­phil­ia B ther­a­py; Al­ler­gan scores sN­DA for Avy­caz

9 years ago
News Briefing

Mi­cro­cap biotech Ocera craters on a PhI­Ib fail­ure for he­pat­ic en­cephalopa­thy

9 years ago
R&D

Fi­bro­Gen, As­traZeneca ready Chi­na ap­pli­ca­tion as ane­mia drug scores in two piv­otal stud­ies

9 years ago
R&D
China

In­cyte grabs con­trol of a can­cer drug from Calithera’s pipeline for $53M up front

9 years ago
Pharma

No­vo Nordisk shrugs off Brex­it, un­veils $144M plan for a di­a­betes re­search cen­ter at Ox­ford

9 years ago
Financing
R&D

Biotech ex­ecs slam Trump’s trav­el ban, count­ing the high cost to a glob­al in­dus­try

9 years ago
Pharma

Reg­u­lus or­dered to re­main in lim­bo as FDA re­fus­es to lift hold, de­mand­ing more da­ta on lead drug

9 years ago
R&D

No­van’s shares in melt­down fol­low­ing "dis­cor­dant" PhI­II stud­ies of a new ac­ne drug

9 years ago
R&D

Ouch: Eli Lil­ly is walk­ing away from Ado­cia deal and its ul­tra-fast in­sulin — for the sec­ond time

9 years ago
R&D

High­land who? Biotech gets a $200M war chest to crack the US AD­HD mar­ket

9 years ago
R&D

Jounce’s Cin­derel­la sto­ry now in­cludes a $102M IPO chap­ter

9 years ago
Financing

No­var­tis silent­ly yanks a trou­bled biosim­i­lar ap­pli­ca­tion; Chi­nese an­ti­body de­vel­op­er draws $39M round

9 years ago
News Briefing

M&A is off to a hot start in 2017; Too bad we can't say the same for gen­der par­i­ty

9 years ago
Bioregnum
Opinion

Sin­ga­pore in­vestors at Temasek grab an $800M stake in Google’s Ver­i­ly

9 years ago
Financing

Ven­rock stocks up on $450M Fund 8 as it pre­pares a new string of biotech deals

9 years ago
Financing
First page Previous page 1132113311341135113611371138 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times